Novartis will ‘walk away from’ deal to buy MorphoSys, STAT’s Feuerstein says

After Novartis (NVS) announced that it intends to buy MorphoSys (MOR), Adam Feuerstein, the Senior Writer in Biotech for STAT, argued that the “deal will not close.” Feuerstein forecasts: “Six months from now, or sooner, Novartis will walk away – slightly embarrassed but otherwise unscathed – happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away. MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.”